Sputnik V Vaccine Trial Data

Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18

Russian scientists leading clinical studies for the Sputnik V COVID-19 vaccine have responded to claims of "serious concerns over interim results from phase 3 trials" by stressing their data meets "clear and transparent standards..."

An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.

The company has submitted the mid-stage trial safety data to India's drug regulator for review and approval to continue late-stage trials

Russian coronavirus vaccine developers published fresh results from their trial of the Sputnik V vaccine on Monday based on new data, and said the shot had again been found to be 91.4 per cent effective in providing protection from COVID-19.

Russia's Sputnik V coronavirus vaccine is 95 percent effective according to a second interim analysis of clinical trial data, its developers said on Tuesday.

Pharmaceutical giant Dr. Reddy's Laboratories today said that it had isolated all its data centre services as a preventive measure following a cyberattack. The drug maker had shut its key plants globally due to the breach at its servers, ET Now had reported, citing sources.

Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18

Russian scientists leading clinical studies for the Sputnik V COVID-19 vaccine have responded to claims of "serious concerns over interim results from phase 3 trials" by stressing their data meets "clear and transparent standards..."

An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.

The company has submitted the mid-stage trial safety data to India's drug regulator for review and approval to continue late-stage trials

Russian coronavirus vaccine developers published fresh results from their trial of the Sputnik V vaccine on Monday based on new data, and said the shot had again been found to be 91.4 per cent effective in providing protection from COVID-19.

Russia's Sputnik V coronavirus vaccine is 95 percent effective according to a second interim analysis of clinical trial data, its developers said on Tuesday.

Pharmaceutical giant Dr. Reddy's Laboratories today said that it had isolated all its data centre services as a preventive measure following a cyberattack. The drug maker had shut its key plants globally due to the breach at its servers, ET Now had reported, citing sources.